Objective To investigate the effect of angiotensin Ⅱ (AngⅡ) type 1 receptor block irbesartan on the expression of renal cyclooxygenase-2 ( COX-2 ) in rats with type 2 diabetes mellitus.Methods 18 rats were divided into control group, diabetes mellitus group and treating group.Immunohistochemistry was used to measure the expression of COX-2, matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1).The urinary TXB2,6-Ket-PGF1 αconcentration was determined by radioimmunoassay at the 6th week .Results There was an increasing expression of COX-2,TIMP-1 and decreasing M MP-9 ( COX-2:0.39 ± 0.02 vs 0.24 ± 0.04, TIMP :0.41 ± 0.03 vs 0.24 ± 0.02,MMP-9:0.24 ± 0.02 vs 0.32 ± 0.02, P ＜ 0.05 ) expression in the diabetes mellitus group ( P ＜ 0.05 ).Irbesartan could increase MMP-9 (0.29 ± 0.03 ) and depress TIMP-1 (0.34 ± 0.02) expression through inhibiting the expression of COX-2(0.31 ± 0.03) in renal tissue.Conclusions COX-2 was involved in the pathogenesis of the injury of type 2 diabetic nephropathy.Irbesartan might exert its renoprotective effects through inhibiting COX-2 activity, modulating the expression of MMP-9 and TIMP-1.

Objective:To obtain a high specificity and high affinity anti-human PD-L1 monoclonal antibody which can be used for clinical diagnosis and block PD-L1 and PD-1 binding.Methods:BALB/c mice were immunized with recombinant PD-L1 protein.The positive cell clones stably secreting anti-human PD-L1 monoclonal antibody were obtained by classical hybridoma cell fusion technique.The specificity,affinity,subtype and other characteristics of the antibody were identified by ELISA.Immunofluorescence and indirect immunofluorescence were used to detect the tumor cells.Antibody blocking activity was confirmed by tumor killing test.Results:Two cell strains stably secreting monoclonal antibodies against human PD-LI were screened out.Abl and Ab2 had high titer and affinity.The antibody titers were 1:2.56×106 and 1:3×105,and the affinity was 1.5×109 L/mol and 2.5×10s L/mol respectively.There was no cross reaction between these two antibodies and PD-L2.Immunoblotting,indirect immunofluorescence confirmed that the antibody can be used to the diagnosis.Experiment showed that PD-L1 antibodies can increases tumor-killing activity of CIK cells.Conclusion:Two hybridoma cell lines capable of stably secreting highly specific and high affinity anti-human PD-L1 monoclonal antibody are obtained.They can specifically bind to PD-L1 molecules on tumor cells and can be used to the diagnosis of tumor phenotype and prognosis.Antibody blocking function can be applied to combined CIK cell immunotherapy.

Objective To compare vein graft quality and patency between the segmental incision and the open saphenous vein harvesting in coronary artery bypass grafting. Methods The data of patients underwent CABG in the First Affiliated Hospital of Wenzhou Medical University from January 2013 to December 2015 were retrospectively analyzed. The patients were devided into 2 groups,which is 99 open and 114 sagmental incision,by the way of harvesting. The operative risk factors,harvesting time and length of venous grafts,as well as the inci-sion complications were compared between the above two groups. One year after operation,the vein graft patency was detected by the coronary artery CTA. Results No significant differences in the risk factors of incision compli-cations were observed between the two groups,but the incidence of various incision complications was significantly reduced in the segmental incision group(P < 0.05). No significant difference in patency rate of venous grafts was observed between two groups at 1 years post?operation. Conclusion Segmental incision saphenous vein harvesting was safe and feasible,which can decrease the incision complications without obvious effect on postoperative patency.

Objective:To explore the changes of serum zinc-2 glycoprotein (ZAG) levels in patients with polycystic ovary syndrome (PCOS) with metabolic indicators, and to seek the correlation between metabolic disorders and ZAG in patients with PCOS, so as to provide a basis for the diagnosis and treatment of metabolic disorders in patients with PCOS.Methods:A total of 200 Han PCOS patients admitted to Shenzhen Hospital of Guangzhou University of Traditional Chinese Medicine (Futian) from January 2017 to June 2018 were selected as the observation group, and divided into the group A (BMI ≥ 25kg/m 2) and the group B (BMI <25kg/m 2) according to body mass index(BMI). Meanwhile, 100 healthy Han women who came to the hospital for physical examination during this period were selected as the control group.ZAG, fasting blood glucose (FPG), fasting insulin (FINS), triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were measured, and the differences among the three groups were compared.After weight control, group A reviewed the above indicators and compared the differences of these indicators before and after weight control. Results:In group A, the FPG, FINS, HOMA-IR, TC, TG, HDL, LDL and ZAG were (5.92±0.51)mmol/L, (19.94±3.15)mIU/L, (5.29±1.19), (5.59±0.49)mmol/L, (2.03±0.35)mmol/L, (0.72±0.21)mmol/L, (3.05±0.43)mmol/L, (35.80±8.12)ng/mL, respectively, which in group B were (5.38±0.62)mmol/L, (15.67±4.59)mIU/L, (3.84±1.45), (4.61±0.65)mmol/L, (1.49±0.35)mmol/L, (1.24±0.40)mmol/L, (2.61±0.40)mmol/L, (45.22±10.27)ng/mL, respectively, which in the control group were (4.77±0.53)mmol/L, (11.66±3.23)mIU/L, (2.52±0.95), (4.59±0.53)mmol/L, (1.39±0.26)mmol/L, (1.40±0.31)mmol/L, (2.50±0.35)mmol/L, (59.15±8.90)ng/mL, respectively, and the differences were statistically significant between group A and group B, between group A and control group, and between group B and control group( F=36.81, 41.04, 44.05, 33.65, 38.61, 39.25, 18.45, 56.88, all P<0.01). After weight control, the FPG, FINS, HOMA-IR, TC, TG, HDL, LDL and ZAG in group A were (5.27±0.54)mmol/L, (15.67±3.16)mIU/L, (3.72±1.06), (4.98±0.45)mmol/L, (1.62±0.30)mmol/L, (1.03±0.25)mmol/L, (2.82±0.43)mmol/L, (43.59±8.20)ng/mL, respectively, and the differences were statistically significant in group A before and after weight control ( t=15.26, 15.67, 17.70, 11.04, 17.61, -9.61, 22.83, -13.79, all P<0.01). The serum ZAG was positively correlated with HDL ( r=0.628, P<0.01), and negatively correlated with BMI ( r=-0.685, P<0.01), HOMA-IR ( r=-0.729, P<0.01), and TC ( r=-0.579, P<0.01). Conclusion:ZAG value is reducedin PCOS patients, with lower level in obesity group, and is positively correlated with HDL, negatively correlated with BMI, HOMA-IR, TC.The metabolism in patients with PCOS can be reflected by ZAG, which has a certain value in diagnosis and treatment of PCOS patients with metabolic disorder, and provides theory basis for further study of the metabolic disorder of PCOS.

Objective To investigate the effects of different ratios of ω-3 polyunsaturated fatty acids(ω-3 PUFA)on depression and cognitive impairment in patients with major depression.Methods A randomized,double-blinded controlled trial was used to randomly assign patients with depression to a cognitive improvement group,a depression improvement group,and a placebo group.The cognitive improvement group took 1388 mg of docosahexaenoic acid(DHA)and 692 mg of eicosapentaenoic acid(EPA)every day and the depression improvement group took 1248 mg of EPA and 832 mg of DHA every day.The placebo group took the same dose of soybean oil for 12 weeks,during which psychiatric medication was maintained.The 24-item Hamilton depression scale(HAMD-24)was used to evaluate depressive symptoms,and the standardized MATRICS consensus cognitive battery(MCCB)was used to evaluate cognitive function after 6 weeks and 12 weeks,respectively.Results The study recruited a total of 46 patients with depression including 22 in the cognitive improvement group,12 in the depression improvement group,and 12 in the placebo group.After 6 weeks of treatment,the HAMD-24 scores were significantly lower in the depression improvement group(19.00±10.70)and cognitive improvement group(16.58±9.39)than in the placebo group(31.10±10.03)(P<0.01).After 12 weeks of treatment,HAMD-24 scores were significantly lower in the depression improvement group(13.58±8.43)than in the placebo group(28.10±15.04)(P=0.02).No significant interaction effect was found on the cognitive assessment scores in any dimension after 6 weeks and 12 weeks of treatment(P>0.05).The incidence rate of adverse events in the depression improvement group was 16.7%(2/12),and no adverse events were reported in the other two groups.There was no significant difference in the incidence of adverse events among the three groups(P=0.13).Conclusion Treatment with ω-3PUFA for 6 weeks can improve the depressive symptoms of patients with depression.The formula with a higher ratio of EPA exhibits higher effectiveness while the two groups of ω-3PUFA formulas with different ratios do not improve cognitive function.